Sensitization of cisplatin-resistant ovarian cancer cells by magnetite iron oxide nanoparticles: an in vitro study

Nanomedicine ◽  
2019 ◽  
Vol 14 (24) ◽  
pp. 3177-3191
Author(s):  
Kurtulus Gokduman

Aim: To investigate potential of magnetite iron oxide nanoparticles (MION) to sensitize cisplatin-resistant ovarian cancer cells to cisplatin, which to the best of found knowledge has not been reported previously. Materials & methods: MION with a diameter of approximately 20 nm were synthesized, and characterized using Fourier transform infrared spectroscopy, powder x-ray diffraction and particle size analyzer. Results: The synthesized MION have increased reactive oxygen species levels and decreased glutathione levels in cisplatin-resistant ovarian cancer cells (OVCAR-3 and SKOV-3). Using MTT, capsase-3 activity and live/dead assays, capability of the synthesized MION to sensitize cisplatin-resistant ovarian cancer cells has been illustrated. Conclusion: Thus, for further investigations, the synthesized MION can be considered as a potent agent enabling much more effective cisplatin-based therapies for ovarian cancer.

2016 ◽  
Vol 4 (1) ◽  
pp. 159-166 ◽  
Author(s):  
Wenting Liu ◽  
Liju Nie ◽  
Fulai Li ◽  
Zoraida P. Aguilar ◽  
Hong Xu ◽  
...  

An effective method for separation and detection of ovarian cancer cells from whole blood using folic acid conjugated magnetic nanoparticles.


2016 ◽  
Vol 4 (47) ◽  
pp. 7741-7748 ◽  
Author(s):  
Li Zhao ◽  
Hongkuan Yang ◽  
Tsukuru Amano ◽  
Hongmei Qin ◽  
Luyi Zheng ◽  
...  

Chlorin e6, loaded on the surface of SPION-PG-Lys8 through electrostatic attraction, was delivered preferentially into mitochondria of SKOV3 ovarian cancer cells, improving efficacy of photodynamic therapy significantly.


2018 ◽  
Vol 3 (2) ◽  
pp. 13
Author(s):  
Michelle Davis

Ovarian cancer is amongst the most life-threatening malignancy of the female reproductive system, whereas 90% of those ovarian cancers are epithelial with an overall poor five-year survival rate of 44% across all stages and all races [1]–[2], [31]. This paper aims to review the current treatment and diagnostic strategies for ovarian cancer [3]. Using grounded substantial research, multiple figures were developed to show the relations of ovarian cancer diagnostics and ovarian cancer therapeutics.  It is a great start to look into what may be causing most patients to become resistant to the current standard of care, platinum-based chemotherapeutics, for ovarian cancer [4]. A comprehensive literature review will be used to understand the genetic basis of the disease and possible cancer growth patterns, so we could possibly introduce better diagnostics and therapeutics [5]. The findings show that there are a variety of treatments options other than the standard of care, platinum-based therapy [6]. Nanoparticle encapsulation therapy is one way that has been approved by the FDA to therapeutically treat ovarian cancer without the platinum resistant side effects [7]. Also, the discovery of different diagnostics for ovarian cancer can help with better individualized treatments for patients with different forms of ovarian cancer [8]. Currently, the only serous diagnostic test for the detection of ovarian cancer is high levels of Cancer Antigen 125 (CA-125), which is only shown in 50% of early staged ovarian cancers [16]. The main treatment option for ovarian cancer is platinum-based drugs, in which most cases of patients with ovarian cancer will become resistant. Detecting and treating ovarian cancer while the cells are small, contained, and still in the early stages in vivo still remains to be a challenge [9]. Here, we will demonstrate the bioelectrical interactions of the ovarian cancer cells fused with the magnetic iron oxide nanoparticles with the use of an MRI. The findings demonstrate that the diagnostic method for the early detection of epithelial ovarian cancer requires the use of magnetic iron oxide nanoparticles with specific ligand external profiles as a contrast reagent to make the small-sized ovarian cancer cells appear more visible under MRI. 


2020 ◽  
Vol 13 ◽  
Author(s):  
Selin Yılmaz ◽  
Çiğdem İçhedef ◽  
Kadriye Buşra Karatay ◽  
Serap Teksöz

Backgorund: Superparamagnetic iron oxide nanoparticles (SPIONs) have been extensively used for targeted drug delivery systems due to their unique magnetic properties. Objective: In this study, it’s aimed to develop a novel targeted 99mTc radiolabeled polymeric drug delivery system for Gemcitabine (GEM). Methods: Gemcitabine, an anticancer agent, was encapsulated into polymer nanoparticles (PLGA) together with iron oxide nanoparticles via double emulsion technique and then labeled with 99mTc. SPIONs were synthesized by reduction–coprecipitation method and encapsulated with oleic acid for surface modification. Size distribution and the morphology of the synthesized nanoparticles were caharacterized by dynamic light scattering(DLS)and scanning electron microscopy(SEM), respectively. Radiolabeling yield of SPION-PLGAGEM nanoparticles were determined via Thin Layer Radio Chromatography (TLRC). Cytotoxicity of GEM loaded SPION-PLGA were investigated on MDA-MB-231 and MCF7 breast cancer cells in vitro. Results: SEM images displayed that the average size of the drug-free nanoparticles was 40 nm and the size of the drug-loaded nanoparticles was 50 nm. The diameter of nanoparticles were determined as 366.6 nm by DLS, while zeta potential was found as-29 mV. SPION was successfully coated with PLGA, which was confirmed by FTIR. GEM encapsulation efficiency of SPION-PLGA was calculated as 4±0.16 % by means of HPLC. Radiolabeling yield of SPION-PLGA-GEM nanoparticles were determined as 97.8±1.75 % via TLRC. Cytotoxicity of GEM loaded SPION-PLGA were investigated on MDA-MB-231 and MCF7 breast cancer cells. SPION-PLGA-GEM showed high uptake on MCF-7, whilst incorporation rate was increased for both cell lines which external magnetic field application. Conclusion: 99mTc labeled SPION-PLGA nanoparticles loaded with GEM may overcome some of the obstacles in anti-cancer drug delivery because of their appropriate size, non-toxic, and supermagnetic characteristics.


2012 ◽  
Vol 48 (2) ◽  
pp. 55-63 ◽  
Author(s):  
M. Muller ◽  
M. Chérel ◽  
P.-F. Dupré ◽  
S. Gouard ◽  
M. Collet ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document